MY106737A - Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4. - Google Patents

Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.

Info

Publication number
MY106737A
MY106737A MYPI90001264A MYPI19901264A MY106737A MY 106737 A MY106737 A MY 106737A MY PI90001264 A MYPI90001264 A MY PI90001264A MY PI19901264 A MYPI19901264 A MY PI19901264A MY 106737 A MY106737 A MY 106737A
Authority
MY
Malaysia
Prior art keywords
interleukin
neutrophils
methods
myeloid cells
purifying
Prior art date
Application number
MYPI90001264A
Inventor
Raman Jay
L Nagabhushan T
Bonnem Eric
Sullivan Lee
Bober Loretta
Chu-Tay Tang John
Naveh David
Grace Michael
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/531,270 external-priority patent/US5077388A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY106737A publication Critical patent/MY106737A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

METHODS FOR INCREASING THE NUMBERS OF NEUTROPHILS AND FOR INDUCING THE MATURATION OF MYELOID CELLS IN MAMMALS BY ADMINISTERING IL-4 ARE DISCLOSED. ALSO DISCLOSED ARE PROCESSES FOR PURIFYING ACTIVE RECOMBINANT HUMAN INTERLEUKIN-4 FROM CERTAIN E. COLI FERMENTATION BROTHS OR FROM CERTAIN CHO-CELL CELL CULTURE MEDIUMS.
MYPI90001264A 1989-07-28 1990-07-26 Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4. MY106737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693789A 1989-07-28 1989-07-28
US07/531,270 US5077388A (en) 1990-05-31 1990-05-31 Purification of human interleukin-4 from a secreted escherichia coli mutant

Publications (1)

Publication Number Publication Date
MY106737A true MY106737A (en) 1995-07-31

Family

ID=27011670

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001264A MY106737A (en) 1989-07-28 1990-07-26 Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.

Country Status (3)

Country Link
IE (2) IE68840B1 (en)
MY (1) MY106737A (en)
NZ (1) NZ234665A (en)

Also Published As

Publication number Publication date
NZ234665A (en) 1997-06-24
IE902718A1 (en) 1991-02-27
IE68840B1 (en) 1996-07-10
IE75354B1 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
WO1991001744A3 (en) Uses of interleukin-4 and method for purifying it
AU630516B2 (en) Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
EP0215126A4 (en) STIMULATION FACTOR OF HUMAN GRANULOCYTE COLONIES.
AU690336B2 (en) Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
HU9201712D0 (en) A mammalian cytokine, il-11
CA2087525A1 (en) Adoptive immunotherapy with interleukin-7
MY102865A (en) Production and use of il-6
AU7177896A (en) Multidrug resistance gene
DE3666347D1 (en) Polyene antibiotic emulsion formulation
ZA887773B (en) Interleukin-7
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
EP0437610A4 (en) Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide
AU621810B2 (en) Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes
HUT44615A (en) Process for preparing gm-cst protein and its derivatives
AU5218998A (en) Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
ES8506806A1 (en) Hypocholesterolemically active protein.
CA2363269A1 (en) Dna vaccination for treatment of autoimmune disease
SE8605459L (en) NEW CELL GROWTH CONTROL FACTOR
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0201800A3 (en) A cholesterol-rich fraction, process therefor and use thereof in cell culture
ES2020176B3 (en) SIZE COMPOSITION OF POLYVINYL ALCOHOL OF HIGH ACTIVITY IN TISSUES, LITTLE FOAMY.
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells